Global Schizophrenia Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Schizophrenia Treatment Market Segmentation, By Therapeutic Class (Third-Generation Antipsychotics, Second-Generation Antipsychotics, and Others), Product Type (Medications, Conventional or Typical Antipsychotic Drugs, Atypical Antipsychotic Drugs, and Therapies), Treatment (Oral and Injectable), End Users (Hospitals Including Hospital Pharmacies, Retail Pharmacies, and Rehabilitation Centres) - Industry Trends and Forecast to 2032

Schizophrenia Treatment Market Size

• The global schizophrenia treatment market size was valued at USD 7.97 billion in 2024 and is expected to reach USD 9.83 billion by 2032, at a CAGR of 2.65% during the forecast period
• This growth is driven by factors such as the increasing prevalence of schizophrenia, advancements in drug development targeting novel mechanisms, and the growing recognition of mental health issues

Schizophrenia Treatment Market Analysis

• Schizophrenia is a type of a chronic disorder that has an undesirable effect on an entity's lifestyle. Schizophrenic patients abnormally construe reality. The disorder results in a variety of behavioural changes that comprise the grouping of delusions and hallucinations
• Schizophrenia treatment is a lifetime procedure, and the medication used for treating schizophrenia controls the activities of patients
• North America is expected to dominate the Schizophrenia Treatments market due to advanced healthcare infrastructure, high healthcare expenditure, and robust research and development activities
• Asia-Pacific is expected to be the fastest growing region in the Schizophrenia Treatment market driven by increasing healthcare investments and improving infrastructure
• Second generation segment is expected to dominate the market with a market share of 72.62% due to their improved safety and efficacy profiles compared to first-generation antipsychotics. These newer drugs, also known as atypical antipsychotics, are associated with a lower risk of extrapyramidal symptoms, such as tremors and rigidity, which are common side effects of older medications

Report Scope and Schizophrenia Treatment Market Segmentation  

Schizophrenia Treatment Market Trends

“Emergence of Novel Treatment Modalities”

• The approval of Cobenfy (KarXT) by the U.S. FDA in September 2024 marked a significant advancement in schizophrenia treatment. Unlike traditional antipsychotics that target dopamine receptors, Cobenfy focuses on muscarinic receptors, offering a novel approach to symptom management
• There is a growing adoption of long-acting injectable antipsychotics, which enhance patient adherence and reduce the frequency of relapses. These formulations are becoming increasingly preferred in clinical settings
•  The incorporation of digital health technologies, such as mobile applications and telemedicine, is transforming schizophrenia management by facilitating remote monitoring and improving patient engagement
• Advancements in genetic profiling and biomarker identification are paving the way for personalized treatment regimens, aiming to optimize efficacy and minimize side effects for individual patients
• Ongoing studies are exploring the potential of adjunctive therapies, including cognitive-behavioral interventions and psychosocial support, to complement pharmacological treatments and enhance overall patient outcomes

Schizophrenia Treatment Market Dynamics

Driver

“Increasing Prevalence and Awareness about the Disease”

• The global prevalence of schizophrenia is on the rise, driven by factors such as urbanization, genetic predisposition, and environmental influences, leading to an increased demand for effective treatment options
• Advancements in diagnostic technologies and increased awareness among healthcare professionals have led to earlier and more accurate detection of schizophrenia, facilitating timely intervention
• Many governments are implementing policies and allocating resources to improve mental health services, including schizophrenia treatment programs, thereby supporting market growth
• Efforts to reduce stigma and educate the public about mental health have encouraged individuals to seek treatment, contributing to a larger patient population in need of care
• The expansion of insurance coverage for mental health services, including schizophrenia treatments, has improved access to care for a broader segment of the population

Opportunity

“Expansion into Emerging Markets”

• Emerging markets, particularly in Asia-Pacific and Africa, present significant opportunities due to large, underserved patient populations and increasing healthcare investments
• Investments in healthcare infrastructure in developing regions are enhancing the availability and quality of mental health services, facilitating the introduction of advanced schizophrenia treatments
• Government initiatives aimed at improving mental health care access and reducing stigma are creating a conducive environment for the introduction of new treatments
• The availability of generic antipsychotic medications in emerging markets makes treatment more affordable, expanding access to care for economically disadvantaged populations
• Changing societal attitudes towards mental health are leading to increased acceptance and willingness to seek treatment, further driving market expansion in these regions

Restraint/Challenge

“Societal Stigma and Treatment Accessibility”

• Despite efforts to raise awareness, stigma surrounding schizophrenia remains prevalent, discouraging individuals from seeking diagnosis and treatment

• The cost of advanced antipsychotic medications and long-term therapy can be prohibitive, especially in low-income regions, limiting patient access to necessary care
• Side effects associated with antipsychotic medications, such as weight gain and sedation, can lead to non-adherence and discontinuation of treatment, affecting overall treatment efficacy
• A shortage of trained mental health professionals in certain regions hampers the delivery of timely and effective schizophrenia care, impacting patient outcomes
• Stringent regulatory processes and lengthy approval timelines for new treatments can delay the availability of innovative therapies, hindering market growth

Schizophrenia Treatment Market Scope

The market is segmented on the basis therapeutic class, product type, treatment, and end users.

In 2025, the second generation is projected to dominate the market with a largest share in therapeutic Class segment

The second-generation segment is expected to dominate the Schizophrenia Treatment market with the largest share of 72.62% in 2025 due to their improved safety and efficacy profiles compared to first-generation antipsychotics. These newer drugs, also known as atypical antipsychotics, are associated with a lower risk of extrapyramidal symptoms, such as tremors and rigidity, which are common side effects of older medications.

The injectable is expected to account for the largest share during the forecast period in treatment market

In 2025, the injectable segment is expected to dominate the market with the largest market share due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications. This delivery method improves patient adherence and simplifies treatment regimens, as injections are needed less frequently than daily oral doses.

Schizophrenia Treatment Market Regional Analysis

“North America Holds the Largest Share in the Schizophrenia Treatment Market”

• North America schizophrenia drugs market held the largest market revenue share of 39.0%. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders
• U.S. is expected to dominate the global schizophrenia treatment market, particularly in the North America region. This dominance is attributed to its clinical trial activities enhance the development and availability of treatment options
• North America leads the global schizophrenia treatment market due to its advanced healthcare infrastructure, high healthcare expenditure, and robust research and development activities ​
• Strong presence of key pharmaceutical companies and extensive clinical trial activities enhance the development and availability of treatment options
• Comprehensive mental health services and favorable reimbursement policies support widespread access to schizophrenia treatments
• Government initiatives and public awareness campaigns further bolster the region's position in the market

“Asia-Pacific is Projected to Register the Highest CAGR in the Schizophrenia Treatment Market”

• Asia Pacific is the fastest-growing region in the global schizophrenia treatment market, driven by increasing healthcare investments and improving infrastructure
• Rising awareness about mental health and government programs targeted at improving mental health treatment contribute to market expansion​
• Large patient populations in countries such as China and India necessitate enhanced treatment options and services
• Launch of new medications in the region, such as Janssen Pharmaceutical's INVEGA TRINZA in China, supports market growth
• Collaborations between local and international stakeholders facilitate the development and distribution of schizophrenia treatments

Schizophrenia Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Johnson & Johnson Services, Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Otsuka Holdings Co. Ltd. (Japan)
• AstraZeneca (U.K.)
• Eli Lilly and Company (U.S.) 
• Alkermes (Ireland)
• Sumitomo Dainippon Pharma Co. Ltd. (Japan)
• Pfizer Inc. (U.S.)
• VANDA PHARMACEUTICALS (U.S.)
• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
• Allergan (U.S.)
• H. Lundbeck A/S (Denmark)
• AVINEURO PHARMACEUTICALS (U.S.)
• Gedeon Richter plc (Hungary)
• Astellas Pharma Inc. (Japan)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• PsychoGenics Inc. (U.S.)
• Merz Pharma (Germany)

Latest Developments in Global Schizophrenia Treatment Market

• In March 2022, AbbVie entered into a new co-development and license agreement with Gedeon Richter, to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases
• In February 2022, Vanderbilt University signed a worldwide license and a research collaboration agreement with Neumora Therapeutics to develop precision medicines for brain diseases through the integration of data science and neuroscience. The license program includes two new series of compounds that targets schizophrenia and other neuropsychiatric disorders 
• In October 2021, Alkermes announced the launch of Lybalvi, an antipsychotic medication for adults with schizophrenia and bipolar I disorder. Lybalvi combines olanzapine, an established antipsychotic, with samidorphan, a new compound, to treat these conditions. The medication aims to offer an effective treatment option with a lower risk of weight gain, a common side effect of antipsychotics
• In June 2021, Alkermes plc received the U.S. Food and Drug Administration (FDA) approval for LYBALVI indicated for the treatment of adults with bipolar disorder and schizophrenia. LYBALVI is an oral atypical antipsychotic drug that offers the efficacy of lanzapine with less weight gain
• In May 2021, Boehringer Ingelheim announced that company had received Breakthrough Therapy Designation (BTD) for BI 425809 from the U.S. Food and Drug Administration (FDA) for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)

SKU-27284